GILEAD SCIENCES, INC. Other Comprehensive Income (Loss), Reclassification Adjustment for Sale of Securities Included in Net Income, Net of Tax (Deprecated 2012-01-31)
GILEAD SCIENCES, INC. (GILD) reported Other Comprehensive Income (Loss), Reclassification Adjustment for Sale of Securities Included in Net Income, Net of Tax (Deprecated 2012-01-31) of $30.60 million for the 3-month period ending 2012-03-31, per its 10-Q filed 2012-05-04.
Discontinued › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeReclassificationAdjustmentForSaleOfSecuritiesIncludedInNetIncomeNetOfTax · last filed 2012-05-04
- GILEAD SCIENCES, INC. other comprehensive income (loss), reclassification adjustment for sale of securities included in net income, net of tax (deprecated 2012-01-31) for the quarter ending 2012-03-31 was $30.60M.
- GILEAD SCIENCES, INC. other comprehensive income (loss), reclassification adjustment for sale of securities included in net income, net of tax (deprecated 2012-01-31) for the quarter ending 2011-09-30 was $2.60M, a 160.00% increase year-over-year.
- GILEAD SCIENCES, INC. other comprehensive income (loss), reclassification adjustment for sale of securities included in net income, net of tax (deprecated 2012-01-31) for the quarter ending 2011-06-30 was $3.10M, a 0.00% change year-over-year.
- GILEAD SCIENCES, INC. other comprehensive income (loss), reclassification adjustment for sale of securities included in net income, net of tax (deprecated 2012-01-31) for the quarter ending 2011-03-31 was -$1.44M, a 259.44% decline year-over-year.
| Period end | Other Comprehensive Income (Loss), Reclassification Adjustment for Sale of Securities Included in Net Income, Net of Tax (Deprecated 2012-01-31) 3 month | Other Comprehensive Income (Loss), Reclassification Adjustment for Sale of Securities Included in Net Income, Net of Tax (Deprecated 2012-01-31) 3 month as first filed | Other Comprehensive Income (Loss), Reclassification Adjustment for Sale of Securities Included in Net Income, Net of Tax (Deprecated 2012-01-31) 6 month | Other Comprehensive Income (Loss), Reclassification Adjustment for Sale of Securities Included in Net Income, Net of Tax (Deprecated 2012-01-31) 9 month |
|---|---|---|---|---|
| 2012-03-31 | $30.60M 10-Q · filed 2012-05-04 | |||
| 2011-09-30 | $2.60M 10-Q · filed 2011-11-04 | $5.70M derived: sum of 2 quarters · filed 2011-11-04 | $7.20M 10-Q · filed 2011-11-04 | |
| 2011-06-30 | $3.10M 10-Q · filed 2011-08-05 | $4.60M 10-Q · filed 2011-08-05 | ||
| 2011-03-31 | -$1.44M 10-Q · filed 2012-05-04 | $1.40M 10-Q · filed 2011-05-09 | ||
| 2010-09-30 | $1.00M 10-Q · filed 2011-11-04 | $4.10M derived: sum of 2 quarters · filed 2011-11-04 | $5.00M 10-Q · filed 2011-11-04 | |
| 2010-06-30 | $3.10M 10-Q · filed 2011-08-05 | $4.00M 10-Q · filed 2011-08-05 | ||
| 2010-03-31 | $900.00K 10-Q · filed 2011-05-09 | |||
| 2009-09-30 | $1.00M 10-Q · filed 2010-11-08 | $2.30M derived: sum of 2 quarters · filed 2010-11-08 | $5.10M 10-Q · filed 2010-11-08 | |
| 2009-06-30 | $1.30M 10-Q · filed 2010-08-09 | $4.10M 10-Q · filed 2010-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMGEN INC (AMGN) | United States | $219.567B | 22.39 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |